It's not every day that a company already worth billions sees its shares nearly triple in a single trading session. Welcome to the world of biotech, because that's exactly what happened to Moderna Inc. (NASDAQ: MRNA) on Wednesday of this week, after the Massachusetts-based company stunned the market with a breakthrough that sent its stock rocketing to a multi-year high.
The catalyst was a set of results from a closely watched trial of an experimental skin cancer vaccine, and the numbers were dramatic enough to reprice the company instantly. Shares closed up a remarkable 177% in a single day, adding to a rally that has seen the stock climb some 465% so far this year.